A Multicenter, Prospective, Single-arm Clinical Study on the Treatment of Refractory/Relapsed Follicular Lymphoma (R/RFL) With Chidamide Combined With Linperlisib

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• The patients diagnosed with follicular lymphoma with grade 1-3a, have received at least second-line systemic treatment, and at least one of the first-line treatments includes anti-CD20 monoclonal antibody (anti-CD20 monoclonal antibody monotherapy or combined chemotherapy). If the latest histopathological diagnosis is more than 6 months, a lymph node or tissue puncture or biopsy (resection or coarse needle puncture) must be performed.

• Age ≥18 years old, regardless of gender.

• The estimated survival time is more than 3 months.

• ECOG ≤ 2.

• Be able to follow the requirements of the research plan.

• The patients have at least one measurable lesion (any length of lymph node lesion \> 1.5cm or any length of extranodal lesion \> 1 cm) examined by computed tomography (CT)/ magnetic resonance imaging (MRI).

• Be able to understand and voluntarily provide informed consent.

Locations
Other Locations
China
Bing Xu
RECRUITING
Xiamen
Contact Information
Primary
Bing Xu
xubingzhangjian@126.com
+8618750918842
Backup
Zhifeng Li
lzf_xm@163.com
+8613606901162
Time Frame
Start Date: 2023-11-22
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 33
Treatments
Experimental: Chidamide combined with Linperlisib
Sponsors
Collaborators: Shanxi Province Cancer Hospital, Fujian Provincial Hospital, Huizhou Municipal Central Hospital, Sun Yat-sen University, Zhangzhou Affiliated Hospital of Fujian Medical University, The First Affiliated Hospital with Nanjing Medical University, Fujian Cancer Hospital, Jieyang People's Hospital, Dongguan People's Hospital
Leads: The First Affiliated Hospital of Xiamen University

This content was sourced from clinicaltrials.gov